Spelman, T. Et Al. 2020. Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis. 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual) , (ELECTR NETWORK), 526-527.

Spelman, T., Acosta, C., Hyde, R., Campbell, N., Havrdova, E., Horakova, D., ... Trojano, M.(2020). Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis . 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual) (pp.526-527). , ELECTR NETWORK

Spelman, T. Et Al. "Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis," 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 2020

Spelman, T. Et Al. "Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis." 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual) , ELECTR NETWORK, pp.526-527, 2020

Spelman, T. Et Al. (2020) . "Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis." 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual) , ELECTR NETWORK, pp.526-527.

@conferencepaper{conferencepaper, author={T. Spelman Et Al. }, title={Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis}, congress name={8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual)}, city={}, country={ELECTR NETWORK}, year={2020}, pages={526-527} }